"目錄號: HY-13635
metabolic Enzyme/Protease -
Finasteride是口服活性的睪酮5α-還原酶抑制劑，Ki為10 nM。
5 alpha Reductase
相關(guān)產(chǎn)品
Dutasteride - Finasteride acetate - CGP-53153 -
生物活性
Description
Finasteride is an orally active testosterone 5-alpha-reductase inhibitor (Ki= 10 nM). Target: 5-alpha ReductaseApproved: 1992Finasteride, a synthetic 4-azasteroid antiandrogen compound, is a specific inhibitor of steroid Type II 5α-reductase, an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). Finasteride is used in the treatment of prostate cancer, benign prostatic hyperplasia, and androgenetic alopecia (male pattern baldness). In benign prostatic hyperplasia, finasteride inhibits 5alpha-reductase activity in epithelium for Ki of 10 nM, significantly lower than in stroma (Ki = 33nM) [1].
Clinical Trial
NCT01133444
Dr. Reddy's Laboratories Limited
Healthy
April 2002
Phase 1
NCT01133457
Dr. Reddy's Laboratories Limited
Healthy
April 2002
Phase 1
NCT01264289
Dr. Reddy's Laboratories Limited
Healthy
November 2006
Phase 1
NCT01264302
Dr. Reddy's Laboratories Limited
Healthy
November 2006
Phase 1
NCT00542243
University Health Network, Toronto-Merck Frosst Canada Ltd.
Enlarged Prostate
February 2008
Phase 3
NCT01296672
The University of Texas Health Science Center at San Antonio-National Institutes of Health (NIH)-National Cancer Institute (NCI)
Prostate Cancer
February 2011
Phase 4
NCT01585441
National Eye Institute (NEI)-The EMMES Corporation-National Institutes of Health Clinical Center (CC)
Retinal Disease
April 2012
Phase 2
NCT02548117
Baylor College of Medicine
ERYTHROCYTOSIS
February 2016
Phase 3
NCT00837252
National Eye Institute (NEI)-National Institutes of Health Clinical Center (CC)
Retinal Disease
February 2009
Phase 1-Phase 2
NCT01227993
National Eye Institute (NEI)-National Institutes of Health Clinical Center (CC)
Retinal Disease
October 2010
Phase 1-Phase 2
NCT00600691
University of British Columbia-Health Canada-Merck Frosst Canada Ltd.
Hematuria-Hematospermia
March 2008
Phase 2
NCT00564460
University of Alberta-Merck Frosst Canada Ltd.
Benign Prostatic Hyperplasia
February 2008
Phase 3
NCT00130767
Hospices Civils de Lyon
Benign Prostatic Hyperplasia
December 2004
Phase 4
NCT00871247
Actavis Inc.
Healthy
November 2004
Phase 1
NCT00870480
Actavis Inc.
Healthy
November 2004
Phase 1
NCT00564252
Iran University of Medical Sciences-Firuzgar hospital affiliated to Iran University of Medical Sciences
Idiopathic Hirsutism
February 2006
NCT02146937
Sidney Kimmel Comprehensive Cancer Center
Detectable Prostate Nodules
March 2014
Phase 2
NCT02055170
CancerCare Manitoba
Non-small Cell Lung Cancer
June 2014
Phase 2
NCT02248701
VA Office of Research and Development-University of Florida
Spinal Cord Injury-Spinal Cord Injuries-Trauma, Nervous System-Wounds and Injuries-Central Nervous System Diseases-Nervous System Diseases-Spinal Cord Diseases-Gonadal Disorders-Endocrine System Diseases-Hypogonadism-Genital Diseases, Male
January 16, 2017
Phase 2
NCT01829893
Korea University Anam Hospital-GL Pharm Tech Corporation
Benign Prostatic Hyperplasia (BPH)
January 2012
Phase 1
NCT00835796
Teva Pharmaceuticals USA
Healthy
June 2002
Phase 1
NCT00835666
Teva Pharmaceuticals USA
Healthy
June 2002
Phase 1
NCT01534351
Merck Sharp & Dohme Corp.
Benign Prostatic Hyperplasia
August 1, 2013
Phase 3
NCT01052870
HairDx, LLC
Androgenetic Alopecia
December 2008
Phase 1
NCT02502669
Elorac, Inc.
NODULOCYSTIC ACNE
July 2015
Phase 2
NCT00438464
National Cancer Institute (NCI)-M.D. Anderson Cancer Center
Adenocarcinoma of the Prostate-Stage II Prostate Cancer
February 2007
Phase 2
NCT00650377
Mylan Pharmaceuticals
Healthy
October 2004
Phase 1
NCT00648791
Mylan Pharmaceuticals
Healthy
September 2004
Phase 1
NCT01174953
University of Kansas-University of Kansas Medical Center
Prostate Cancer
July 2010
NCT01391156
Mae Fah Luang University Hospital
Androgenetic Alopecia
March 2011
Phase 3
NCT02483195
University of Florida
Female Androgenetic Alopecia
August 2016
Phase 4
NCT02244229
Boehringer Ingelheim
Prostatic Hyperplasia
April 1998
Phase 4
NCT00736645
Roswell Park Cancer Institute
Prostate Cancer
August 2008
Phase 2
NCT00396175
Merck Sharp & Dohme Corp.
Androgenetic Alopecia
March 1998
Phase 3
NCT01231607
GlaxoSmithKline
Androgenetic Alopecia
October 2010
Phase 3
NCT01923090
University of Birmingham
Healthy Volunteers
August 2012
Phase 2
NCT02791243
Polichem S.A.
Androgenetic Alopecia
May 9, 2016
Phase 1
NCT01139762
Eli Lilly and Company
Benign Prostatic Hyperplasia-Enlarged Prostate
September 2010
Phase 3
NCT01736033
Seoul National University Hospital-Astellas Pharma Korea, Inc.-Medical Research Collaborating Center, Seoul, Korea
Benign Prostate Hyperplasia
February 2012
Phase 4
NCT02703220
VA Office of Research and Development
Sleep Apnea-Elderly Adults
July 3, 2015
Phase 4
NCT03004469
Polichem S.A.
Alopecia, Androgenetic
July 2016
Phase 3
NCT00475501
VA Office of Research and Development-Endo Pharmaceuticals-Merck Sharp & Dohme Corp.
Male Hypogonadism-Muscle Atrophy-Sarcopenia-Benign Prostate Hypertrophy
January 2007
Phase 2
NCT00759135
Nymox Corporation
Benign Prostatic Hyperplasia (BPH)-Enlarged Prostate
May 2007
Phase 2
NCT00064649
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-Diagnostic Ultrasound-Urologix-Medtronic-Merck Sharp & Dohme Corp.-Sanofi-Synthelabo
Benign Prostatic Hyperplasia
April 2004
Phase 3
NCT00021814
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Prostatic Hyperplasia-Prostatic Hypertrophy, Benign
December 1995
Phase 3
NCT01342367
University of Chicago
Prostate Cancer
December 2010
NCT00663793
University of Washington-National Institutes of Health (NIH)-Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contraception-Hypogonadism
October 2008
Phase 1
NCT00003323
Alliance for Clinical Trials in Oncology-National Cancer Institute (NCI)
Prostate Cancer-Sexual Dysfunction and Infertility
May 1998
Phase 2
NCT01643629
Kasiak Research Pvt. Ltd.
Androgenetic Alopecia
January 2012
Phase 1-Phase 2
NCT00127179
Merck Sharp & Dohme Corp.
Benign Prostatic Hyperplasia
January 1, 2004
Phase 3
View MoreCollapse
References
[1]. Weisser, H. and M. Krieg, In vitro inhibition of androstenedione 5alpha-reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia. J Steroid Biochem Mol Biol, 199
metabolic Enzyme/Protease -
Finasteride是口服活性的睪酮5α-還原酶抑制劑，Ki為10 nM。
5 alpha Reductase
相關(guān)產(chǎn)品
Dutasteride - Finasteride acetate - CGP-53153 -
生物活性
Description
Finasteride is an orally active testosterone 5-alpha-reductase inhibitor (Ki= 10 nM). Target: 5-alpha ReductaseApproved: 1992Finasteride, a synthetic 4-azasteroid antiandrogen compound, is a specific inhibitor of steroid Type II 5α-reductase, an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). Finasteride is used in the treatment of prostate cancer, benign prostatic hyperplasia, and androgenetic alopecia (male pattern baldness). In benign prostatic hyperplasia, finasteride inhibits 5alpha-reductase activity in epithelium for Ki of 10 nM, significantly lower than in stroma (Ki = 33nM) [1].
Clinical Trial
NCT01133444
Dr. Reddy's Laboratories Limited
Healthy
April 2002
Phase 1
NCT01133457
Dr. Reddy's Laboratories Limited
Healthy
April 2002
Phase 1
NCT01264289
Dr. Reddy's Laboratories Limited
Healthy
November 2006
Phase 1
NCT01264302
Dr. Reddy's Laboratories Limited
Healthy
November 2006
Phase 1
NCT00542243
University Health Network, Toronto-Merck Frosst Canada Ltd.
Enlarged Prostate
February 2008
Phase 3
NCT01296672
The University of Texas Health Science Center at San Antonio-National Institutes of Health (NIH)-National Cancer Institute (NCI)
Prostate Cancer
February 2011
Phase 4
NCT01585441
National Eye Institute (NEI)-The EMMES Corporation-National Institutes of Health Clinical Center (CC)
Retinal Disease
April 2012
Phase 2
NCT02548117
Baylor College of Medicine
ERYTHROCYTOSIS
February 2016
Phase 3
NCT00837252
National Eye Institute (NEI)-National Institutes of Health Clinical Center (CC)
Retinal Disease
February 2009
Phase 1-Phase 2
NCT01227993
National Eye Institute (NEI)-National Institutes of Health Clinical Center (CC)
Retinal Disease
October 2010
Phase 1-Phase 2
NCT00600691
University of British Columbia-Health Canada-Merck Frosst Canada Ltd.
Hematuria-Hematospermia
March 2008
Phase 2
NCT00564460
University of Alberta-Merck Frosst Canada Ltd.
Benign Prostatic Hyperplasia
February 2008
Phase 3
NCT00130767
Hospices Civils de Lyon
Benign Prostatic Hyperplasia
December 2004
Phase 4
NCT00871247
Actavis Inc.
Healthy
November 2004
Phase 1
NCT00870480
Actavis Inc.
Healthy
November 2004
Phase 1
NCT00564252
Iran University of Medical Sciences-Firuzgar hospital affiliated to Iran University of Medical Sciences
Idiopathic Hirsutism
February 2006
NCT02146937
Sidney Kimmel Comprehensive Cancer Center
Detectable Prostate Nodules
March 2014
Phase 2
NCT02055170
CancerCare Manitoba
Non-small Cell Lung Cancer
June 2014
Phase 2
NCT02248701
VA Office of Research and Development-University of Florida
Spinal Cord Injury-Spinal Cord Injuries-Trauma, Nervous System-Wounds and Injuries-Central Nervous System Diseases-Nervous System Diseases-Spinal Cord Diseases-Gonadal Disorders-Endocrine System Diseases-Hypogonadism-Genital Diseases, Male
January 16, 2017
Phase 2
NCT01829893
Korea University Anam Hospital-GL Pharm Tech Corporation
Benign Prostatic Hyperplasia (BPH)
January 2012
Phase 1
NCT00835796
Teva Pharmaceuticals USA
Healthy
June 2002
Phase 1
NCT00835666
Teva Pharmaceuticals USA
Healthy
June 2002
Phase 1
NCT01534351
Merck Sharp & Dohme Corp.
Benign Prostatic Hyperplasia
August 1, 2013
Phase 3
NCT01052870
HairDx, LLC
Androgenetic Alopecia
December 2008
Phase 1
NCT02502669
Elorac, Inc.
NODULOCYSTIC ACNE
July 2015
Phase 2
NCT00438464
National Cancer Institute (NCI)-M.D. Anderson Cancer Center
Adenocarcinoma of the Prostate-Stage II Prostate Cancer
February 2007
Phase 2
NCT00650377
Mylan Pharmaceuticals
Healthy
October 2004
Phase 1
NCT00648791
Mylan Pharmaceuticals
Healthy
September 2004
Phase 1
NCT01174953
University of Kansas-University of Kansas Medical Center
Prostate Cancer
July 2010
NCT01391156
Mae Fah Luang University Hospital
Androgenetic Alopecia
March 2011
Phase 3
NCT02483195
University of Florida
Female Androgenetic Alopecia
August 2016
Phase 4
NCT02244229
Boehringer Ingelheim
Prostatic Hyperplasia
April 1998
Phase 4
NCT00736645
Roswell Park Cancer Institute
Prostate Cancer
August 2008
Phase 2
NCT00396175
Merck Sharp & Dohme Corp.
Androgenetic Alopecia
March 1998
Phase 3
NCT01231607
GlaxoSmithKline
Androgenetic Alopecia
October 2010
Phase 3
NCT01923090
University of Birmingham
Healthy Volunteers
August 2012
Phase 2
NCT02791243
Polichem S.A.
Androgenetic Alopecia
May 9, 2016
Phase 1
NCT01139762
Eli Lilly and Company
Benign Prostatic Hyperplasia-Enlarged Prostate
September 2010
Phase 3
NCT01736033
Seoul National University Hospital-Astellas Pharma Korea, Inc.-Medical Research Collaborating Center, Seoul, Korea
Benign Prostate Hyperplasia
February 2012
Phase 4
NCT02703220
VA Office of Research and Development
Sleep Apnea-Elderly Adults
July 3, 2015
Phase 4
NCT03004469
Polichem S.A.
Alopecia, Androgenetic
July 2016
Phase 3
NCT00475501
VA Office of Research and Development-Endo Pharmaceuticals-Merck Sharp & Dohme Corp.
Male Hypogonadism-Muscle Atrophy-Sarcopenia-Benign Prostate Hypertrophy
January 2007
Phase 2
NCT00759135
Nymox Corporation
Benign Prostatic Hyperplasia (BPH)-Enlarged Prostate
May 2007
Phase 2
NCT00064649
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-Diagnostic Ultrasound-Urologix-Medtronic-Merck Sharp & Dohme Corp.-Sanofi-Synthelabo
Benign Prostatic Hyperplasia
April 2004
Phase 3
NCT00021814
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Prostatic Hyperplasia-Prostatic Hypertrophy, Benign
December 1995
Phase 3
NCT01342367
University of Chicago
Prostate Cancer
December 2010
NCT00663793
University of Washington-National Institutes of Health (NIH)-Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contraception-Hypogonadism
October 2008
Phase 1
NCT00003323
Alliance for Clinical Trials in Oncology-National Cancer Institute (NCI)
Prostate Cancer-Sexual Dysfunction and Infertility
May 1998
Phase 2
NCT01643629
Kasiak Research Pvt. Ltd.
Androgenetic Alopecia
January 2012
Phase 1-Phase 2
NCT00127179
Merck Sharp & Dohme Corp.
Benign Prostatic Hyperplasia
January 1, 2004
Phase 3
View MoreCollapse
References
[1]. Weisser, H. and M. Krieg, In vitro inhibition of androstenedione 5alpha-reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia. J Steroid Biochem Mol Biol, 199
110102000668（1）號